Breaking News Instant updates and real-time market news.

AGN

Allergan

$238.06

1.71 (0.72%)

, BIIB

Biogen

$272.94

0.48 (0.18%)

12:25
04/24/17
04/24
12:25
04/24/17
12:25

Piper Jaffray biopharma analysts hold an analyst/industry conference call

Biopharmaceuticals Analysts Schimmer and Amsellem, along with Dr. Jeffrey Gudin, Co-director of the Pain Management Center at Englewood Hospital, discuss the role of opioids in managing chronic pain, the potential advantages of Nektar's NKTR-181 compared to other abuse deterrent opioids currently on the market, and evaluate tamper-resistant opioids COLL's Xtampza ER, EGLT's Arymo ER, TEVA's Vantrela ER and Purdue's OxyContin on an Analyst/Industry conference call to be held on April 24 at 1 pm.

AGN

Allergan

$238.06

1.71 (0.72%)

BIIB

Biogen

$272.94

0.48 (0.18%)

CARA

Cara Therapeutics

$16.53

-0.56 (-3.28%)

COLL

Collegium Pharmaceutical

$10.24

0.19 (1.89%)

EGLT

Egalet

$4.24

0.02 (0.47%)

ENDP

Endo

$10.29

-0.19 (-1.81%)

NKTR

Nektar

$18.37

-0.76 (-3.97%)

PFE

Pfizer

$33.82

0.18 (0.54%)

TEVA

Teva

$31.81

0.68 (2.18%)

  • 24

    Apr

  • 25

    Apr

  • 02

    May

  • 03

    May

  • 04

    May

  • 04

    May

  • 07

    May

  • 09

    May

  • 11

    May

  • 31

    May

  • 06

    Jun

  • 08

    Jun

  • 27

    Aug

  • 30

    Aug

AGN Allergan
$238.06

1.71 (0.72%)

04/06/17
OPCO
04/06/17
NO CHANGE
Target $43
OPCO
Outperform
Teva Austedo approval 'a nice incremental positive,' says Oppenheimer
Oppenheimer analyst Derek Archila notes that Teva (TEVA) received approval for Austedo for Huntington's chorea, which he sees as "a nice positive" given the company's recent challenges. Based on his review of the label and recent physician checks, the analyst believes Austedo could potentially become first-line therapy for Huntington's chorea and forecasts sales of about $600M by 2022 in this indication. Archila continues to like Teva's shares long term, though he expects they may be range-bound until a new CEO is hired, generic business stabilizes, and Allergan's (AGN) stake in Teva is resolved. He reiterates an Outperform rating and $43 price target on Teva's shares.
04/06/17
WELS
04/06/17
NO CHANGE
WELS
Allergan Botox data shows potential efficacy in depression, says Wells Fargo
Wells Fargo says that Phase II data on Allergan's Botox as a treatment for depression was mixed but indicated that the drug could have efficacy as a depression treatment. The firm says that investors could soon start to view Botox for depression as "another legitimate large shot on goal" for Allergan. Wells keeps an Outperform rating on the shares.
04/18/17
WELS
04/18/17
NO CHANGE
WELS
Allergan partnership a 'promising free option,' says Wells Fargo
Wells Fargo analyst David Maris views Allergan's (AGN) partnership with Novartis (NVS) to conduct a Phase IIb study using its cenicriviroc and Novartis's lead FXR agonist for the treatment of nonalcoholic steatohepatitis as a "promising free option." The deal is a way to maximize Allergan's shots-on-goal in combination NASH treatments, Maris tells investors in a research note. He has an Outperform rating on Allergan shares.
04/21/17
SBSH
04/21/17
NO CHANGE
Target $270
SBSH
Buy
Allergan removed from U.S. Focus List at Citi
Citi analyst Liav Abraham removed Allergan from her firm's U.S. Focus List citing the rally in the shares since late 2016. The analyst, however, keeps a buy rating on Allergan and upped her price target for the stock to $270 from $245. Evidence of execution on key pipeline assets is likely required for further share upside, Abraham tells investors in a research note.
BIIB Biogen
$272.94

0.48 (0.18%)

04/11/17
CHDN
04/11/17
NO CHANGE
Target $50
CHDN
Buy
REGENXBIO price target raised to $50 from $35 at Chardan
Chardan analyst Gbola Amusa raised his price target on REGENXBIO (RGNX) to $50 from $35, calling the company's appointment of Olivier Danos from Biogen (BIIB) as Chief Scientific Officer a "watershed moment" that increases his conviction in the company's long-term prospects. Amusa keeps a Buy rating on REGENXBIO shares.
04/07/17
LEER
04/07/17
NO CHANGE
Target $290
LEER
Market Perform
Biogen price target lowered to $290 from $300 at Leerink
Leerink analyst Geoffrey Porges lowered his price target for Biogen (BIIB) to $290 from $300 on valuation and reiterated a Market Perform rating on the shares. Last week, the FDA granted approval to its competitor Roche's (RHHBY) Ocrevus for the treatment of both relapsing remitting multiple sclerosis and primary progressive multiple sclerosis, the analyst points out, adding that he believes Ocrevus will be a "game changer" in multiple sclerosis treatment.
04/04/17
JMPS
04/04/17
DOWNGRADE
JMPS
Market Perform
Forward Pharma downgraded on patent loss at JMP Securities
As noted earlier, JMP Securities downgraded Forward Pharma to Market Perform from Outperform. Analyst Jason Butler downgraded the stock after the Patent Trial and Appeal Board of the United States Patent and Trademark Office decided that all the company's '187 patent claims against Biogen (BIIB) are invalid. Butler believes that Forward's stock is fairly valued at current levels.
04/04/17
SBSH
04/04/17
NO CHANGE
Target $315
SBSH
Buy
Citi reiterates Buy on Biogen after SMA survey
Citi analyst Robyn Karnauskas says her follow-up spinal muscular atrophy survey supports her 2017 thesis on Biogen. The survey, with same doctors to assess the progress of Biogen's Spinraza launch, suggests 11% of the SMA patients have already started on the drug, Karnauskas tells investors in a research note. 18% of the patients have been prescribed Spinraza, up from 10% in the analyst's last survey in January. Karnauskas believes the Q1 consensus of $20M in Spinraza revenue looks achievable. She keeps a Buy rating on Biogen with a $315 price target.
CARA Cara Therapeutics
$16.53

-0.56 (-3.28%)

04/06/17
PIPR
04/06/17
NO CHANGE
Target $27
PIPR
Overweight
Cara Therapeutics price target raised to $27 from $23 at Piper Jaffray
Piper Jaffray analyst Charles Duncan raised his price target for Cara Therapeutics to $27 saying the company's increased cash position reduces the risk to fund "significant "Phase III progress in uremic pruritus and postop pain into the second half of 2019. The analyst sees a buying opportunity and current share levels and keeps an Overweight rating on Cara shares.
03/28/17
LDLW
03/28/17
NO CHANGE
Target $35
LDLW
Buy
Cara Therapeutics price target raised to $35 from $20 at Laidlaw
Laidlaw analyst Jim Molloy raised Cara Therapeutics' price target to $35 from $20 saying this morning's Phase 2b trial data of IV CR845 for for moderate to severe pruritus in dialysis patients is a "huge positive." Molly tells investors CR845 is potentially a "blockbuster" indication, which is also being tested for post-operative pain and osteoarthritis of the knee pain, with data expected on those indications in 2H 2017. Molloy has a Buy rating on Cara shares.
03/28/17
HCWC
03/28/17
NO CHANGE
Target $30
HCWC
Buy
Cara Therapeutics price target raised to $30 from $22 at H.C. Wainwright
H.C. Wainwright analyst Corey Davis raised his price target for Cara Therapeutics to $30 saying this morning's data from its I.V. form of CR845 in treating uremic pruritis is "even better than expected." On the primary endpoint, 845 showed an "impressive" 68% reduction in itching at the eight week endpoint, which was even better than the 54% reduction seen in the previous Phase 2a trial that lasted only two weeks, Davis tells investors in a research note. The analyst keeps a Buy rating on the shares. In pre-market trading, Cara shares are up 15%, or $2.69, to $20.84.
03/10/17
JANY
03/10/17
NO CHANGE
Target $20
JANY
Buy
Cara Therapeutics price target raised to $20 from $18 at Janney Capital
Janney Capital analyst Ken Trbovich highlighted that results from Part A of Cara Therapeutics' uremic pruritus study are expected later this month and that the company anticipates reporting results from its Phase 2b study in osteoarthritis pain and an interim analysis from the adaptive Phase 3 study in postoperative pain in Q2. He raised his fair value estimate for Cara shares to $20 from $18 ahead of these potential catalysts and keeps a Buy rating on the stock.
COLL Collegium Pharmaceutical
$10.24

0.19 (1.89%)

06/23/16
PIPR
06/23/16
NO CHANGE
Target $27
PIPR
Overweight
Piper says doctor survey reinforces confidence in uptake of Collegium's Xtampza
After surveying 32 physicians with significant experience prescribing extended-release opioids, Piper Jaffray analyst David Amsellem said the responses reinforced his view that Collegium's Xtampza ER will likely gain significant traction. The analyst reiterates an Overweight rating on Collegium and bumped up his price target on shares to $27 from $26 to reflect new Xtampza ER estimates and inclusion of recently acquired Onsolis.
09/13/16
GABE
09/13/16
INITIATION
Target $23
GABE
Buy
Collegium Pharmaceutical initiated with a Buy at Gabelli
Gabelli initiated Collgium with a Buy and a $23 price target.
02/01/17
02/01/17
NO CHANGE

Collegium Pharmaceutical's Xtampza meets endpoints in drug abuse trial
Collegium Pharmaceutical announced topline results from an oral human abuse potential clinical trial, designed to evaluate the abuse potential and pharmacokinetics of oral administration of Xtampza ER compared to chewed Xtampza ER, and crushed immediate-release oxycodone in solution in non-dependent, recreational drug abusers. The study met its primary and secondary endpoints of lower "Drug Liking" and "Take Drug Again". The results demonstrated that intact and chewed Xtampza ER had statistically significantly lower peak "Drug Liking" when compared with crushed immediate-release oxycodone. Furthermore, Xtampza ER when taken chewed was bioequivalent to taking it intact as determined by Cmax and AUC. Intact and chewed Xtampza ER (fed or fasted) also demonstrated statistically significant lower "Take Drug Again" when compared with crushed immediate-release oxycodone. Statistically significant differences in peak effects between intact and chewed Xtampza ER treatments compared with crushed IR oxycodone were seen for many other secondary endpoints such as "overall drug liking", "feeling high", "any drug effects", and "good drug effects".
02/02/17
JANY
02/02/17
NO CHANGE
Target $25
JANY
Buy
Collegium trial likely to lead to better Xtampza label, says Janney Capital
Janney Capital analyst Ken Trbovich said he sees the results of the oral human abuse potential study of Xtampza as likely to lead to improved language in the drug's label, which will further differentiate it from market leader OxyContin. The analyst, who adds that Xtampza's launch continues to slowly pick up pace and he continues to expect formulary wins with Express Scripts (ESRX) and United Healthcare (UNH), keeps a Buy rating and $25 fair value estimate on Collegium Pharmaceutical (COLL) shares.
EGLT Egalet
$4.24

0.02 (0.47%)

09/13/16
GABE
09/13/16
INITIATION
Target $9.5
GABE
Buy
Egalet initiated with a Buy at Gabelli
Gabelli initiated Egalet with a Buy and a $9.50 price target.
10/26/16
JANY
10/26/16
NO CHANGE
JANY
Neutral
Egalet's Arymo faces increased risk from Morphabond, says Janney Capital
Janney Capital analyst Ken Trbovich noted that privately held Inspirion Delivery Sciences entered into a collaboration agreement that gives Daiichi Sankyo rights to commercialize Morphabond, which means that product may be commercialized before Egalet's Arymo, which is "tied up in a delay of unknown duration" with the FDA. Morphabond being the first abuse-deterrent, extended-release morphine-based product to launch without a blackbox warning for co-ingestion with alcohol will make it more difficult for Egalet to gain traction with Arymo, said Trbovich, who keeps a Neutral rating on the shares.
01/10/17
STFL
01/10/17
NO CHANGE
STFL
Egalet Arymo outlook still positive, says Stifel
After the FDA approved Egalet's Arymo pain medicine but did not approve an oral or intranasal claim, Stifel analyst Annabel Samimy still thinks the drug has a large market opportunity and room for penetration. She keeps a $21 price target and a Buy rating on the shares.
01/10/17
GABE
01/10/17
DOWNGRADE
GABE
Hold
Egalet downgraded to Hold from Buy at Gabelli
ENDP Endo
$10.29

-0.19 (-1.81%)

01/31/17
JEFF
01/31/17
NO CHANGE
Target $24
JEFF
Buy
Jefferies says new approvals now even more critical for Akorn
After Endo (ENDP) received approval for Corphedra, the second FDA approved formulation of ephedrine after Avadel Pharmaceuticals' (AVDL), Jefferies analyst David Steinberg says new product approvals are now even more critical to Akorn's (AKRX) 2017 outlook and share price. Both Endo and Avadel will compete with Akorn's largest product, Steinberg tells investors in a research note. His model assumes Akorn's ephedrine sales will decline to $80M in FY17 from $230M in FY16. The analyst keeps a Buy rating on Akorn, however, saying the shares look "very inexpensive" on "multiple valuation metrics."
02/21/17
ADAM
02/21/17
INITIATION
Target $14
ADAM
Hold
Endo initiated with a Hold at Canaccord
Canaccord analyst Dewey Steadman initiated Endo with a Hold and a $14 price target.
02/22/17
02/22/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. NVIDIA (NVDA) initiated with a Buy at Rosenblatt and with a Neutral at MKM Partners. 2. Intel (INTC) initiated with a Sell at Rosenblatt and a Buy at MKM Partners. 3. Goldman Sachs (GS) and Morgan Stanley (MS) initiated with a Neutral at Compass Point. 4. Endo (ENDP) initiated with a Hold at Canaccord. 5. Juno Therapeutics (JUNO) was initiated with an Outperform at Wells Fargo, while Kite Pharma (KITE) was initiated with a Market Perform. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/24/17
RHCO
02/24/17
NO CHANGE
RHCO
Avadel Pharmaceuticals price target lowered to $13 from $17 at SunTrust
SunTrust analyst John Boris reduced his price target on Avadel (AVDL) after Endo (ENDP) launched an injectable drug that will compete, at a similar price point, with Avadel's Akovaz. The analyst adds that Avadel's Bloxiverz is also being challenged by Merck's (MRK) Bridion which is taking share in the neostigmine market. He lowered his estimates for Avadel below consensus levels but keeps a Buy rating on the name.
NKTR Nektar
$18.37

-0.76 (-3.97%)

03/21/17
JPMS
03/21/17
NO CHANGE
Target $24
JPMS
Overweight
Nektar price target raised to $24 from $18 at JPMorgan
JPMorgan analyst Jessica Fye raised her price target for Nektar Therapeutics to $24 citing the positive phase III results for NKTR-181 in pain. The analyst sees a "strong probability" that Nektar partners the drug through the rest of phase III development and to commercialization. She keeps an Overweight rating on the shares.
03/21/17
JEFF
03/21/17
NO CHANGE
Target $25
JEFF
Buy
Nektar price target raised to $25 from $17 at Jefferies
Jefferies analyst David Steinberg raised his price target for Nektar Therapeutics to $25 citing the "unexpected" Phase 3 success for NKTR-181. In a research note tiled "NKTR-181 Back From the Dead; Could Become a Major Product in Chronic Pain," Steinberg says the drug could become the company's largest and most profitable product since it directly addresses the "opioid epidemic." NKTR-181 could bring "significant value" to Nektar as early as 2020, the analyst contends. Steinberg adds that the company now fits his takeover thesis. He keeps a Buy rating on the shares.
03/20/17
ROTH
03/20/17
NO CHANGE
Target $31
ROTH
Buy
Roth Capital raises Nektar price target to $31 after 'impressive' opioid data
Roth Capital analyst Michael Higgins called Nektar's Phase 3 results for NKTR-181 "impressive" and said he expect management will now enter into negotiations to out-license the drug while meeting with the FDA. Higgins, who believes the drug is worth $2B by "conservatively" estimating its value at 3-4X peak sales, raised his price target on Nektar shares to $31 from $23 and reiterates a Buy rating on the stock.
03/20/17
PIPR
03/20/17
NO CHANGE
Target $29
PIPR
Overweight
Nektar price target raised to $29 after opioid trial success at Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said he thought prospects of success for NKTR-181 were very low after a failed Phase 2 study but he was "happy to be proven wrong" after the SUMMIT trial succeeded. A human abuse liability study will read-out around mid-2017, after which the company will meet with the FDA to discuss whether the package for NKTR-181 is adequate for filing, Schimmer noted. He raised his price target on Nektar shares to $29 from $25 and keeps an Overweight rating on the stock, which he calls his "top mid-cap biotech stocks for other reasons," such as its multiple royalty streams from partnered products and its emerging immuno-oncology platform.
PFE Pfizer
$33.82

0.18 (0.54%)

02/21/17
LEER
02/21/17
NO CHANGE
LEER
Outperform
Warning letter raises concerns on Momenta Copaxone catalyst, says Leerink
Leerink analyst Jason Gerberry notes that Momenta (MNTA) disclosed that its generic Copaxone 40mg ANDA will be delayed by an FDA warning letter at its fill-finish manufacturing partner, Pfizer (PFE). The analyst says that while a short delay to Momenta/Novartis' (NVS) g-Copaxone 40mg is not reason for concern, longer delays could diminish the market opportunity as there are four other generic challengers, but none have been able to prove bioequivalence to Teva's (TEVA) lower strength. He reiterates an Outperform rating on Momenta's shares.
03/06/17
FBCO
03/06/17
NO CHANGE
FBCO
Near-Term acquisition of Bristol-Myers unlikely, says Credit Suisse
Credit Suisse analyst Vamil Divan says there is increasing investor focus on strategic actions and opportunities around Bristol-Myers (BMY) following the company's recent stumbles and the increased stake activist investors have taken in the stock. The analyst notes that "the big question" remains whether any of its peers may be interested in an outright acquisition, with Pfizer (PFE), Novartis (NVS) and Gilead (GILD) among the possible acquirers. While the numbers may make sense, Divan sees an acquisition in the next 9-12 months as unlikely as he needs more clarity on some of the large unknowns in the lung cancer market and macro issues such as corporate tax reform.
03/14/17
LEER
03/14/17
NO CHANGE
LEER
Monitoring requests put Novartis Kisqali at marketing disadvantage, says Leerink
Leerink analyst Seamus Fernandez notes that Novartis (NVS) announced the FDA approval of its CDK4/6 inhibitor Kisqali in combination with an aromatase inhibitor for the first-line treatment of post-menopausal women with hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer. The analyst says that the label contains warnings for QT prolongation as well as liver toxicity, both of which necessitate frequent monitoring. Although Kisqali appears to have similar efficacy to Pfizer (PFE) approved Ibrance, the latter's label does not include these warnings or monitoring requirements, he points out, adding that he continues to see Ibrance maintaining long-term market dominance in the CDK4/6 class.
04/16/17
PIPR
04/16/17
DOWNGRADE
Target $124
PIPR
Neutral
Incyte downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Joshua Schimmer downgraded Incyte (INCY) to Neutral and cut his price target for the shares to $124 from $140. The biopharmaceutical company closed Thursday up $2.57 to $140.84. Incyte and Eli Lilly (LLY) announced Friday that the FDA issued a complete response letter for baricitinib, indicating a need to determine appropriate doses. This setback could take years and lead to approval of only the lower dose, leaving potentially little differentiation from Pfizer's (PFE) rheumatoid arthritis treatment Xeljanz," Schimmer tells investors in a research note. The analyst prefers to wait for a "cleaner entry point" into the shares.
TEVA Teva
$31.81

0.68 (2.18%)

04/12/17
JEFF
04/12/17
NO CHANGE
Target $43
JEFF
Buy
Jefferies views Alder concerns as overblown, sees buying opportunity
After spending time with an intellectual property expert, Jefferies analyst Brian Abrahams believes IP concerns relating to Alder Biopharmaceuticals (ALDR) remain overdone. He does not believe Teva's (TEVA) patents will be upheld as valid in the U.S. Abrahams does not think IP conflicts would dissuade potential partners and/or acquirers and keeps a Buy rating on Alder with a $43 price target. The analyst sees a buying opportunity at current levels into the Phase III data.
04/12/17
LEER
04/12/17
NO CHANGE
Target $68
LEER
Outperform
Neurocrine Valbenazine approved with 'best case,' says Leerink
Following Neurocrine's (NBIX) announcement of FDA approval of Ingrezza, or valbenazine, for adults with Tardive Dyskinesia, Leerink analyst Paul Matteis says that the language in the label looks to be a best-case scenario for the company as it outlines few safety risks and does not contain a black box warning for increased risk of suicidality. The analyst believes the latter adds to valbenazine's advantages over Teva's (TEVA) SD-809. Matteis moved his odds of FDA approval from 90% to 100%, reiterated an Outperform rating on Neurocrine's stock and raised his price target on the shares to $68 from $65.
04/21/17
SBSH
04/21/17
NO CHANGE
Target $42
SBSH
Buy
Teva risk/reward favorable at current share levels, says Citi
Citi analyst Liav Abraham views Teva's risk/reward profile as favorable at current share levels. The analyst's analysis suggests some upside to consensus FY17 generics estimates. Abraham acknowledges investor caution ahead of the new CEO announcement, and lowered her price target for the shares to $42 from $47, but she keeps a Buy rating on Teva.

TODAY'S FREE FLY STORIES

KMX

CarMax

$68.84

0.17 (0.25%)

, FINL

Finish Line

$9.22

-0.21 (-2.23%)

20:25
09/21/17
09/21
20:25
09/21/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

KMX

CarMax

$68.84

0.17 (0.25%)

FINL

Finish Line

$9.22

-0.21 (-2.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Sep

HPE

HP Enterprise

$13.79

0.16 (1.17%)

18:47
09/21/17
09/21
18:47
09/21/17
18:47
Periodicals
HP Enterprise planning approximately 5,000 job cuts, Bloomberg reports »

In part of a broader…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 11

    Dec

RP

RealPage

$39.35

-0.1 (-0.25%)

18:41
09/21/17
09/21
18:41
09/21/17
18:41
Hot Stocks
RealPage expects $3M-$4M of renter's insurance claims from hurricanes »

RealPage announced that a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPE

HP Enterprise

$13.79

0.16 (1.17%)

18:39
09/21/17
09/21
18:39
09/21/17
18:39
Periodicals
Breaking Periodicals news story on HP Enterprise »

HP Enterprise planning…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 11

    Dec

YUM

Yum! Brands

$76.48

0.11 (0.14%)

18:37
09/21/17
09/21
18:37
09/21/17
18:37
Conference/Events
Yum! Brands management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

MAR

Marriott

$107.57

-0.12 (-0.11%)

18:32
09/21/17
09/21
18:32
09/21/17
18:32
Conference/Events
Marriott management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

ESPGY

Esprit Holdings

$1.21

0.018 (1.51%)

18:29
09/21/17
09/21
18:29
09/21/17
18:29
Conference/Events
Esprit Holdings management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

BA

Boeing

$256.04

0.58 (0.23%)

18:18
09/21/17
09/21
18:18
09/21/17
18:18
Hot Stocks
Boeing: Turkish Airlines announces intent to order 40 787-9 Dreamliners »

Boeing and Turkish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

M

Macy's

$21.16

-0.32 (-1.49%)

18:18
09/21/17
09/21
18:18
09/21/17
18:18
Conference/Events
Macy's management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

TAHO

Tahoe Resources

$5.60

0.02 (0.36%)

18:12
09/21/17
09/21
18:12
09/21/17
18:12
Hot Stocks
Tahoe Resources raises 2017 gold operations view to 400K-500K »

Tahoe Resources updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATKR

Atkore

$18.42

0.02 (0.11%)

18:11
09/21/17
09/21
18:11
09/21/17
18:11
Conference/Events
Atkore management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

YOGA

YogaWorks

$4.00

-0.04 (-0.99%)

, TXN

Texas Instruments

$86.05

0.22 (0.26%)

18:11
09/21/17
09/21
18:11
09/21/17
18:11
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

YOGA

YogaWorks

$4.00

-0.04 (-0.99%)

TXN

Texas Instruments

$86.05

0.22 (0.26%)

PSDO

Presidio

$13.95

-0.06 (-0.43%)

VSAR

Versartis

$21.60

-0.25 (-1.14%)

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 21

    Sep

FTR

Frontier Communications

$11.69

-0.31 (-2.58%)

18:10
09/21/17
09/21
18:10
09/21/17
18:10
Hot Stocks
Frontier Communications operations in Florida return to near-normal levels »

Daily operations for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLYA

Playa Hotels & Resorts

$10.66

-0.06 (-0.56%)

18:07
09/21/17
09/21
18:07
09/21/17
18:07
Hot Stocks
Playa Hotels & Resorts reports no significant damage from Maria »

Playa Hotels &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

, VSAR

Versartis

$21.60

-0.25 (-1.14%)

18:07
09/21/17
09/21
18:07
09/21/17
18:07
Hot Stocks
Ascendis spikes higher after Versartis Velocity trial fails to meet endpoint »

Shares of Ascendis Pharma…

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

VSAR

Versartis

$21.60

-0.25 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$103.90

-0.04 (-0.04%)

18:04
09/21/17
09/21
18:04
09/21/17
18:04
Hot Stocks
Celanese increases price of acetyl intermediates »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DNOW

NOW Inc.

$12.98

0.1 (0.78%)

18:03
09/21/17
09/21
18:03
09/21/17
18:03
Conference/Events
NOW Inc. management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 01

    Nov

JOBS

51job

$58.50

0.01 (0.02%)

18:02
09/21/17
09/21
18:02
09/21/17
18:02
Hot Stocks
51job announces strategic investment in Lagou »

51job announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HES

Hess Corp.

$43.63

0.17 (0.39%)

17:53
09/21/17
09/21
17:53
09/21/17
17:53
Conference/Events
Hess Corp. management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

APC

Anadarko

$48.49

3.68 (8.21%)

17:43
09/21/17
09/21
17:43
09/21/17
17:43
Recommendations
Anadarko analyst commentary at MUFG »

Anadarko buyback a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

HCC

Warrior Met Coal

$23.28

-1.05 (-4.32%)

17:42
09/21/17
09/21
17:42
09/21/17
17:42
Hot Stocks
Warrior Met Coal receives favorable IRS private letter ruling »

Warrior Met Coal reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAA

MAA

$107.27

-0.03 (-0.03%)

17:35
09/21/17
09/21
17:35
09/21/17
17:35
Hot Stocks
MAA announces estimated impact of Hurricanes Irma and Harvey »

MAA announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$280.42

0.38 (0.14%)

17:31
09/21/17
09/21
17:31
09/21/17
17:31
Hot Stocks
Northrop Grumman awarded $124.7M government contract »

Northrop Grumman Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$205.72

1.45 (0.71%)

17:29
09/21/17
09/21
17:29
09/21/17
17:29
Hot Stocks
General Dynamics Electric Boat awarded $5B government contract »

General Dynamics Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAN

Aaron's

$38.83

-0.39 (-0.99%)

17:19
09/21/17
09/21
17:19
09/21/17
17:19
Hot Stocks
Aaron's provides update on impact of Hurricane Irma »

Aaron's plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.